StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Level 3 Contingent Consideration Liabilities by Quarter

Level 3 Contingent Consideration Liabilities — Ending Fair Value ($M) ($M)

QuarterlyAnnual

Amgen Level 3 Contingent Consideration Liabilities: $171M in Q2 2026, up 90.0% from a year earlier.

Latest, Q2 2026
171
Period ended Jun 30, 2026
Change on a year earlier
+90.0%
90 in Q2 2025
History
40 quarters
Since Q4 2015
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Fair Value Measurements Note (Level 3 Rollforward) (XBRL).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLevel 3 Contingent Consideration Liabilities — Ending Fair Value ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026171+90.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026173+66.3%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025161+51.9%Form 10-Q (filed 2026-08-05) ↗
Q3 2025Sep 30, 202595-15.2%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 202590-15.9%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 2025104+8.3%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 2024106+10.4%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024112+14.3%Form 10-Q (filed 2024-10-31) ↗
Q2 2024Jun 30, 2024107-56.9%Form 10-Q (filed 2024-10-31) ↗
Q1 2024Mar 31, 202496-64.8%Form 10-Q (filed 2024-08-07) ↗
Q4 2023Dec 31, 202396-64.4%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 202398-67.5%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023248-20.0%Form 10-Q (filed 2024-10-31) ↗
Q1 2023Mar 31, 2023273-17.3%Form 10-Q (filed 2024-08-07) ↗
Q4 2022Dec 31, 2022270-21.1%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022302+762.9%Form 10-Q (filed 2023-10-31) ↗

Breakdown

What makes up level 3 Contingent Consideration Liabilities

Cite this data

StockData. (2026). Amgen Level 3 Contingent Consideration Liabilities ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/cc-liab-tot

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.